TPAI A.I CyberSecurity Scoring
05/06/2026
Access Monitoring Plan
Access Monitoring Plan
TAKEDA PHARMACEUTICALS AMERICA, INC. has 34.64% fewer incidents than the average of same-industry companies with at least one recorded incident.
TAKEDA PHARMACEUTICALS AMERICA, INC. has 4.76% fewer incidents than the average of all companies with at least one recorded incident.
TAKEDA PHARMACEUTICALS AMERICA, INC. reported 1 incidents this year: 0 cyber attacks, 0 ransomware, 0 vulnerabilities, 1 data breaches, compared to industry peers with at least 1 incident.
Pharmaceutical Manufacturing
We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms
Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.
A vertically integrated, Global Pharmaceutical Company. Established in 1989, we are engaged in developing, manufacturing, and marketing a wide range of formulations across several major therapeutic areas including anti-infectives, cardiovascular, anti-diabetic, dermatology, and hormone treatment. We develop, manufacture, and globally distribute a broad range of pharmaceutical products across therapies in multiple dosage forms such as solid orals, liquid orals, topical formulations, injectables (Dry Powder) metered dose inhalers and dry powder inhalers. Our Vision To be a leading global pharmaceutical company by providing high quality, affordable and innovative therapeutic solutions for patients with diverse medical needs. Our Mission To contribute towards improving patients’ quality of life across the globe, by providing effective and accessible medicines.
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, aesthetics and other areas of unmet need. Learn more about us at www.abbvie.com and review our community guidelines at https://www.abbvie.com/social-media-community-guidelines.html.
Sun Pharma is the world's fourth-largest speciality generic pharmaceutical company and No. 1 in India. We provide high-quality, affordable medicines trusted by customers and patients in over 100 countries. Sun Pharma's global presence is supported by more than 40 manufacturing facilities spread across 5 continents, R&D centres across the globe, and a multicultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities comprising around 3,000 scientists and R&D investments of over 6-8% of annual revenues. At Sun, our people are our greatest asset. Ours has never been a story of individual brilliance but of cultivating a culture of realising collective potential. In our journey, everyone is enabled to take charge in an environment that offers limitless growth opportunities. We are with you every step of the way, so you can shine for years to come. With the launch of our Employee Value Proposition (EVP), we define our promise to ‘Create Your Own Sunshine'—driven by the three pillars of Better Every Day, Take Charge, and Thrive Together. These pillars drive progress at Sun so that people can achieve what they would have thought impossible. Learn more about our EVP here: https://sunpharma.com/careers/
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA
At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.
Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 23,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.
Latest updates, reports, and threat intel affecting the global network.
HedgeDoc is an open source, real-time collaborative markdown notes application. Prior to 1.11.0, the GitHub Gist export flow created an OAuth2 state value but only checked that it was present rather than validating it against the value expected for the user's session. Because the state was not properly validated, an attacker could forge a callback URL containing their own valid GitHub OAuth code. When processing the callback, HedgeDoc used the victim's logged-in session to select which note to export, but the attacker's authorization code to determine which GitHub account received it. As a result, a logged-in victim who clicked a crafted link could export their own private, protected, or limited note directly into a Gist controlled by the attacker. This issue has been fixed in version 1.11.0.
HedgeDoc is an open source, real-time, collaborative, markdown notes application. Prior to version 1.11.0, HedgeDoc was vulnerable to a YAML alias bomb due to unsafe processing of the note frontmatter. HedgeDoc parsed frontmatter with js-yaml.load (js-yaml v3) via @hedgedoc/meta-marked, which resolved YAML anchor aliases. A compact malicious payload could therefore expand into a huge object structure, consuming excessive CPU. This expansion ran on every request to the publish view (/s/<shortid>) and, when placed under the opengraph key, the editor view (/<noteId>). A ten-level alias bomb could block the single Node.js event loop for roughly 235 seconds per request, causing concurrent requests to hang or drop and rendering the instance unavailable (DoS). Because the note was stored in the database, the impact survived process restarts until the note was removed. toobusy-js did not reliably mitigate the worst cases, as the event loop was saturated before the middleware could respond. This issue was fixed in version 1.11.0.
Crypt::OpenSSL::X509 versions before 2.1.3 for Perl allow a heap out-of-bounds read via a long certificate extension OID in hv_exts. When building the extension hash (via extensions(), extensions_by_long_name(), extensions_by_oid(), or has_extension_oid()), the code passes OBJ_obj2txt()'s return value as the hash-key length; because that value is the OID's full text length rather than the bytes written to the fixed-size buffer (129 bytes), an OID whose text is longer than the 129-byte buffer causes a read past the allocation, exposing adjacent heap memory as the returned hash key. extensions_by_name() uses the static shortname path and is not affected.
Crypt::OpenSSL::X509 versions before 2.1.3 for Perl allow denial of service via NULL pointer dereference. X509V3_EXT_d2i(ext) returns NULL when an extension's DER value fails to parse. basicC, ia5string, and auth_att dereference its result without a NULL check. keyid_data also dereferences akid->keyid, which is NULL for an empty AKI SEQUENCE (DER 30 00) even when the parse succeeds. A caller invoking an affected helper on an extension from an untrusted certificate triggers a SIGSEGV that crashes the Perl process.
Cockpit CMS contains a path traversal vulnerability in the Bucket file storage API (/system/buckets/api). The api() method in modules/System/Controller/Buckets.php sanitizes the bucket name with preg_replace('/[^a-zA-Z0-9-_\\.]/','', $bucket), which permits '..' and '../' sequences. The sanitized value is interpolated into a Flysystem path as uploads://buckets/{bucket}. Flysystem's WhitespacePathNormalizer resolves 'buckets/..' to the empty string (the uploads storage root) without raising PathTraversalDetected because the '..' has a preceding component to consume. An authenticated low-privileged user can send a crafted request with a '../' bucket name to list, upload, and delete files across all buckets, including those belonging to other users or roles
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.